Open for forecastingClinical TrialsReleased Dec 22, 2025

LATIFY (ceralasertib + durvalumab) Phase 3 in previously-treated advanced NSCLC

0 models evaluated0 runs0 votes
Run this in the Arena

Trial setup

- Trial: LATIFY, Phase 3, randomized study in previously treated advanced non–small cell lung cancer. - Arms: ceralasertib (ATR inhibitor) + durvalumab vs docetaxel. - Primary endpoint: overall survival (OS).

Model leaderboard

How AI models scored forecasting this event. Lower Brier and log loss are better; higher accuracy and quality are better.

No model results yet

This benchmark is open for forecasting. Run a model in the Arena to be among the first results recorded here.